The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...

Understanding the ins and outs of a rare disease like atypical hemolytic uremic syndrome (aHUS) is a difficult task for ...

Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

The biggest risers on the FTSE 100 were Prudential, up 39.4p to 722p, Entain, up 36p to 696p, Barratt Redrow, up 23.1p to 460 ...

Recognising that challenge, AstraZeneca's rare disease unit Alexion has launched an interactive storybook that can help ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

Artificial intelligence (AI) can greatly help in this direction, as evidenced by a partnership between the pharmaceutical giant AstraZeneca and Qure.ai. Through its AI-powered tool, qXR, this ...

The World Health Organization wants to tackle inequity and bureaucracy relating to clinical trials. Will its latest guidance make a difference? Anna Volkmer reports During the covid-19 pandemic the UK ...

Astrazeneca Pharma India advanced 1.21% to Rs 7557.05 after the company's standalone net profit surged to Rs 54.68 crore in Q3 FY25 as compared with Rs 15.80 crore in Q3 FY24.

Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...